The most consequential delays in early drug development often occur between decisions. By aligning nonclinical, clinical, bioanalytical, manufacturing, and CRO services teams around shared milestones, sponsors can reduce avoidable handoffs, support timely decisions, and keep decisions, data, and execution moving together.

What You'll Learn:

  • Where gaps between development stages create delays and why generating data on time is only part of the solution.
  • How proactive planning and clear accountability help teams translate emerging data into coordinated action.
  • including adaptive trial planning, parallel workstreams, and early regulatory alignment.
  • The role of project management in multi-site trials, from identifying enrollment risks to coordinating data, teams, and decisions.
  • How an integrated development strategy supported a novel incretin-based therapeutic, progressing from safety assessment to proof-of-concept topline results in 22 months.

Closing the Gaps Between Data and Decisions

Increasingly complex therapies require more sophisticated study designs, specialized testing, and coordinated execution. Even when individual teams meet their milestones, a program can lose valuable time if protocol development, assay validation, regulatory planning, and clinical operations are not aligned.

Bioanalysis at the Finish Line: Supporting Clinical Studies

Antifungal Small Molecule Aerosol Application

Norbert Makori headshot
Dr. Norbert Makori,

When you select a drug development partner, scientific expertise, quality, therapeutic experience, timelines, and technology all matter. They are essential to moving your program forward. But there’s another factor that can be just as important to the success of the relationship: what it feels like to work together.

When Nonclinical Studies Need a Test Article Adjustment, Integration Matters

Nature Biomedical Engineering: Development of an Investigational Epigenetic Silencer Therapy to Transcriptionally Inactivate Viral DNA in Chronic Hepatitis B

For sponsors running clinical trials in Canada, regulatory affairs has long been measured by a familiar set of expectations and milestones: a clean clinical trial application, a Notice of No Objection (NNO), amendments and notifications filed on time, and inspection records that hold up under review. That work remains essential.

Subscribe to